We have therefore studied PI3K/mTOR/Akt pathway activity in basal-like and luminal-like breast cancer xenografts, and the effect of the pan-Akt inhibitor MK-2206 and the dual PI3K/mTOR inhibitor BEZ235 in these models in vivo. The gene discussed is PIK3CA; the disease is breast cancer.